The progression-free survival (PFS) rate of Polivy (generic name: polatuzumab vedotin) has not been explicitly stated in the information provided. However, it was mentioned that Polivy is a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and a rituximab product [1].

In a clinical trial, Polivy plus bendamustine and rituximab showed a significant improvement in PFS and overall survival (OS) compared to bendamustine and rituximab alone in patients with relapsed or refractory DLBCL [1].

According to DrugPatentWatch.com, Polivy was approved by the FDA in June 2019 [2].

In conclusion, while the exact PFS rate of Polivy is not available, it has demonstrated efficacy in improving PFS and OS in DLBCL patients when used in combination with bendamustine and a rituximab product.

Sources:
[1] FDA. (2019). FDA approves Polivy for diffuse large B-cell lymphoma. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polivy-diffuse-large-b-cell-lymphoma>
[2] DrugPatentWatch.com. (n.d.). Polivy (polatuzumab vedotin-piiq). <https://www.drugpatentwatch.com/drugs/polivy>